Novo Nordisk
Q1 2022 Earnings Call
Apr 29, 2022, 7:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Hello, and welcome to the Novo Nordisk Q1 2022 results call. [Operator instructions] Today, I'm pleased to present Lars Fruergaard Jorgensen. Please go ahead with your meeting.
Lars Fruergaard Jorgensen -- President and Chief Executive Officer
Thank you very much. Welcome to this Novo Nordisk earnings call for the first three months of 2022 and outlook for the year. This call follows the early announcement and raise guidance published earlier today. Due to securities regulations, we had to advance the release that was originally scheduled for Wednesday next week.
My name is Lars Fruergaard Jorgensen, and I'm the CEO of Novo Nordisk. With me today, I have executive vice president and head of commercial strategy and corporate affairs, Camilla Sylvest; executive vice president and head of North America operations, Doug Langa; executive vice president and head of development, Martin Holst Lange; and finally, chief financial officer, Karsten Munk Knudsen. All of us will be available for the Q&A session. Today's announcement and the slides for this call are available on our website, novonordisk.com.
Please note that this call is being webcast live and a recording will be made available on our website as well. The call is scheduled to last for one hour. Please turn to the next slide. The presentation is structured as outlined on Slide 2.
Please note that all sales and operating profit growth statements will be at constant exchange rates unless otherwise specified. The Q&A session will begin in about 25 minutes. Please turn to Slide 3. As always, I need to advise you that this call will contain forward-looking statements.
Such are subject to risks and uncertainties that could cause actual results to differ materially from expectations. For further information on the risk factors, please see the company announcement for the first three months of 2022 and the slide prepared for this presentation. Please turn to the next slide. In the first three months of 2022, we delivered double-digit sales and operating profit growth which was -- which has enabled us to raise our outlook for the full year.
I would like to start this call by going through the performance highlights across our strategic aspirations before handing over the word to my colleagues. Within purpose and sustainability, we reached an important milestone with a positive scientific opinion from EMA on human insulin. This will allow for more flexible storage without refrigeration for three rigs if kept below 30 degrees sensors. This positive opinion will support obtaining approval from local health authorities in low and middle-income countries.